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Abstract: Background: Sodium selenite at high dose exerts antitumor effects and increases 
efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the 
safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory 
to cytostatic drugs in a phase I trial. Patients received first line of chemotherapy following 
selenite treatment to investigate altered sensitivity to these drugs and preliminary assessment 
of any clinical benefits. Materials and Methods: Thirty-four patients with different therapy 
resistant tumors received iv sodium selenite daily for consecutive five days either for two 
weeks or four weeks. Each cohort consisted of at least three patients who received the same 
daily dose of selenite throughout the whole treatment. If 0/3 patients had dose-limiting 
toxicities (DLTs), the study proceeded to the next dose-level. If 2/3 had DLT, the dose was 
considered too high and if 1/3 had DLT, three more patients were included. Dose-escalation 
continued until the maximum tolerated dose (MTD) was reached. MTD was defined as the 
highest dose-level on which 0/3 or 1/6 patients experienced DLT. The primary endpoint was 
safety, dose-limiting toxic effects and the MTD of sodium selenite. The secondary endpoint 
was primary response evaluation. Results and Conclusion: MTD was defined as 10.2 mg/m2, 
with a calculated median plasma half-life of 18.25 h. The maximum plasma concentration of 
selenium from a single dose of selenite increased in a nonlinear pattern. The most common 
adverse events were fatigue, nausea, and cramps in fingers and legs. DLTs were acute, of short 
duration and reversible. Biomarkers for organ functions indicated no major systemic toxicity. In 
conclusion, sodium selenite is safe and tolerable when administered up to 10.2 mg/m2 under 
current protocol. Further development of the study is underway to determine if prolonged 
infusions might be a more effective treatment strategy. 
Keywords: sodium selenite; carcinoma; pharmacokinetics; maximum tolerated dose 
 
1. Introduction 
The micronutrient selenium is an essential trace element and confers its antioxidant properties upon 
incorporation into selenoproteins with oxidoreductase functionalities. However, redox active free 
selenium compounds at moderate to high doses are capable of perturbing cellular redox homeostasis 
upon generating ROS [1]. Increased ROS production exerts potent cytotoxic effects on proliferating 
cancer cells that exhibit lower threshold tolerance to ROS in comparison to normal cells [2,3]. Hence, 
ROS-producing agents, including redox active selenium compounds comprise a new class of cancer 
therapeutics targeting deregulated redox homeostasis in cancer cells. Specifically, high doses of sodium 
selenite exhibit promising antitumor activities as exemplified in many preclinical studies, both in vitro 
and in vivo. Pharmacodynamics data suggest that selenite targets several key cancer-associated signaling 
pathways and induces multimodal regulated cell death pathways [4–7]. Several studies have reported 
higher cytotoxicity of selenite to tumor cells compared to non-malignant cells at comparable dose [8–10], 
thereby presenting a plausible therapeutic window. We and others have previously shown that drug-resistant 
cancer cells are more sensitive to selenite than their drug-sensitive variants both in vitro [11–13] and in 
transplantable animal models [14]. In experimental carcinogenesis and transplantable tumor models, 
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high dose of selenite prevents against the tumorigenesis and the progression of established  
carcinoma [15–18]. Together, the specificity of selenite to target cancer cells and especially those of 
drug-resistant variants highlights the key properties of selenite as a potent anticancer agent. 
In spite of promising findings in a majority of these preclinical investigations, no systematic clinical 
studies have been carried out to evaluate the therapeutic potential of this compound in cancer patients. 
Two independent studies in the early twentieth century reported subjective improvement, prolonged life 
span and disease free survival in a fraction of patients with inoperable carcinoma following iv administration 
of colloidal selenium [19,20]. So far, selenite pharmacodynamics data are only available in sepsis 
patients with neither increased incidence of acute toxicity symptoms nor higher frequency of adverse 
events when administered with a bolus-loading dose of 2.0 mg Se followed by continuous infusion of 
1.6 mg Se per day for 10 days [21]. Another study has reported similar finding on the incidences of adverse 
events following iv administration of comparable dose of selenite in sepsis patients [22]. However, lack 
of pertinent pharmacokinetics and safety data in dose-escalation studies and presumed high toxicity of 
selenite to humans have limited its potential application as a cancer therapeutic.  
In view of the much anticipated investigation aiming at evaluating the efficacy of selenite in the 
treatment of cancer, the present phase I study was designed to evaluate the safety, establish the MTD of 
iv administered selenite and preliminary efficacy evaluation following termination of selenite treatment 
and subsequent treatment with cancer therapeutics in cancer patients with advanced disease. Based on 
the previous studies, we postulated that selenite might work as a remedy against cancer in three ways: 
the antitumor effect by itself, by reversing chemoresistance and by ameliorating toxic effects from 
chemotherapy. In accordance, each patient was treated with identical chemotherapy as their first line of 
treatment following the assessment of the selenite effect. This made it possible to compare the toxicity 
and primary anti-tumor effects before and after selenium administration. 
2. Experimental Section 
2.1. Patient Eligibility 
Inclusion criteria comprised confirmed malignant disease with progressing tumor in spite of treatment 
with established drugs for respective diagnosis, capacity to cooperate, a good or fairly good performance 
status (WHO performance status 0–2), and age above 18 years. The exclusion criteria consisted of any 
other complicating disease interfering with the possibility to carry through the study and any other cancer 
treatment 3 weeks prior the treatment commencement. The study was approved by the Ethical Committee of 
Stockholm (2006/429-31/3), the Swedish Medical Products Agency and registered in EU Clinical Trial 
Register (Eudra CT Number: 2006-004076-13). All patients provided informed consent prior to receiving 
the treatments. 
2.2. Study Design 
This phase I trial was an open-label dose-escalation study of iv administered sodium selenite as a 
single agent. Detailed study design is presented in Figure 1 and dose escalation schedule is described in 
Table 1.  
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Figure 1. Schematic diagram depicting the study design. The first 13 patients were treated 
as per the initial study protocol that was amended and Patients 14–34 were subjected to new 
treatment schedule. For detailed information on the specific chemotherapeutic interventions in 
each patient, please refer to Supplementary Table S1. 160 × 41 mm (300 × 300 DPI). 
Table 1. Dose Exposure/Escalation Design. 
Cohort 
No. 
No. of 
Patients 
Daily Dose 
(mg/m2) 
Treatment Schedule 
Total Median dose (mg); 
(range) 
1 3 0.5 OPD; 5 d/week; 4 weeks 18.0 (17.5–18.0) 
2 3 1.0 OPD; 5 d/week; 4 weeks 36.8 (34.0–42.0) 
3 3 1.5 OPD; 5 d/week; 4 weeks 60.0 (50.0–62.0) 
4 4 2.0 OPD; 5 d/week; 4 weeks 72.5 (66.5–92.0) 
Protocol amendment; 50% dose escalation in subsequent cohorts 
5 4 3.0 OPD; 5 d/week; 2 weeks 49.0 (28.8–57.5) 
6 3 4.5 OPD; 5 d/week; 2 weeks 74.0 (62.0–98.0) 
7 3 6.8 OPD; 5 d/week; 2 weeks 117.0 (115.0–131.0) 
8 3 10.2 OPD; 5 d/week; 2 weeks 214.0 (176.0–225.0) 
9 6 15.3 OPD; 5 d/week; 2 weeks 77.7 (58.0–326.0) 
10 2 12.8 OPD; 5 d/week; 2 weeks 159.8 (107.6–212.0) 
Table 1: Dose is expressed as “total” selenium equivalent, not as selenite. One patient in cohort 3 received 
19/20 treatments and another patient in cohort 4 received 5/10 treatments. At 15.3 mg/m2 dose, only one patient 
received all the planned treatment. Rest of the patients in this cohort received a total of 2–5 treatments (median 
value 3) following which treatment was stopped either due to onsets of grade 3–4 SAE or at patients’ own 
discretion. Note that cohort 10 received a dose of 12.8 mg/m2 to define whether MTD lies within an 
intermediate dose. An example: For a patient with surface area 1.72 m2 receiving 10.2 mg/m2 dose, the daily 
dose is equal to 17.544 mg (1.72 m2 × 10.2 mg/m2). Surface area calculation: √(height × weight/3600); where height 
is in cm and weight is in kg. [23]. Abbreviation: OPD—once per day. 
Each cohort consisted of at least 3 patients who were treated at escalating dose levels according  
to a predefined schedule. The patients received the same daily dose of selenite throughout the whole 
treatment. If 0/3 patients had DLT, the study proceeded to the next dose-level. If 2/3 had DLT, the dose 
was considered too high and if 1/3 had DLT, 3 more patients were included. Dose-escalation continued 
until the MTD was reached. MTD was defined as the highest dose-level on which 0/3 or 1/6 patients 
experienced DLT. To further titrate the MTD, an intermediate dose was chosen in between the dose 
resulted in high DLT and the nearest lower dose with acceptable toxicity. 
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2.3. Drug, Dose Escalation Design and Infusion Schedule 
GMP grade sodium selenite (Intro-Selen i.v., Pharma Nord ApS, Denmark) was used for the  
study. The first cohort was treated daily with 0.5 mg/m2 selenium, equivalent to 1.1 mg/m2 selenite, thus 
approximately a total dose of 0.9 mg selenium per day for a medium sized Swedish patient. The first 13 
patients (first 4 cohorts) received 10 treatments during 2 weeks (no treatment during weekends). Following 
a week of rest, all the patients received the same treatment for another 2 weeks. The objectives of the 
prolonged treatment were to achieve a gradual increase of plasma selenium concentration and  
to detect any serious toxicity at the earliest. Initially, the dose escalation for a successive new cohort was 
0.5 mg/m2. However, after initial plasma selenium levels measurement in the study cohorts receiving up 
to 2.0 mg/m2 dose, we found no or very limited increase in plasma selenium level in the 3rd and 4th week. 
Therefore, an amended protocol was adopted in which the treatment schedule was changed to 10 
treatments during 2 weeks with a faster dose-escalation (50% dose escalation for each new cohort). 
Selenite was administered during 20 min in the first 21 patients. Since each vial comprised only 0.4 mg 
selenium in 10 mL, Patient 22 to Patient 29 received the treatment for 40 minutes to avoid too high 
infusion volumes at short duration. From patient 30 and later, the infusion was given during 4 h. 
Pretreatment with betametason and omeprazol were routinely given to patients at dose levels of 10.2 mg/m2 
and above. 
2.4. Toxicity Assessment 
With a few exceptions, all patients visited OB before and after inclusion, at least once a week during 
the treatment, before each chemotherapy treatment and at the end-of-treatment. At these occasions, 
medical history was recorded and physical examination was performed. Patients underwent CT 
examination one week before the start, 3 days after the completion of selenite treatment and after the 
final chemotherapy treatment. From Patient 27, the first and second CT examinations were substituted 
with PET-CT examination. Routine blood parameters were analyzed before, during and after the treatment. 
ECG was examined before the start and after both the selenite and chemotherapy treatments. 
2.5. Chemotherapy 
All patients had earlier received 1 up to 4 lines of chemotherapy pertinent to the respective diagnosis. 
Detailed description of chemotherapy regimen for each patient is presented in supplementary Table S1. 
Progression in spite of any treatment was an inclusion criterion. We thought that it was of potential 
clinical interest to assess chemotherapy-induced toxicity after selenite treatment knowing that most of 
the patients experienced depleted bone marrow reserves after receiving 2–4 lines of chemotherapy. 
Consequently, being in significantly worse general condition compared with what was the case when 
receiving their first line of chemotherapy also rendered the patients more vulnerable to toxicity. Such 
assessment was performed by administering the same chemotherapy treatment following selenite 
treatment in each patient. This gave an opportunity to compare both the toxicity and effect of primary 
treatment from patient records and the subsequent chemotherapy regimen. It is important to note that the 
idea of implementing chemotherapy after the selenite treatment may not be comprehended as combined 
treatment strategy. Rather, this approach opened up the possibility to evaluate the modulatory effects of 
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selenite treatment on toxicity arising out of subsequent chemotherapy and also to study the possible 
reversal of chemoresistance following selenite treatment. 
2.6. Pharmacokinetic Evaluation 
2.6.1. Blood Sampling and Selenium Analysis 
Blood samples were collected about 5 min prior and post infusion at all treatments. The plasma 
fractions were obtained by centrifugation and stored at –70 °C until analyses. Selenium (as 82Se) in the 
plasma samples was quantified by ICP-MS, as described previously [24] (for details, see data supplement). 
2.6.2. Pharmacokinetic Analyses 
Pharmacokinetic analyses were performed by using the Win-Nonlin program Standard Edition 
version 1.5 (Pharsight Corporation, Mountain View, CA, USA). The one compartment infusion model 
was used for the evaluation of the pharmacokinetics. The reciprocal concentrations were used as weights 
for the iterative procedure. The output from the curve fitting program gives the area under the plasma 
selenium concentration–time curve (AUC) for a single dose, calculated from the fitted  
zero-time intercepts and exponential rate constants of a one exponential function giving AUC values 
from time zero to infinity. AUC values during the entire treatment period (i.e., from day 0 to day 35) 
were evaluated by applying the trapezoidal rule to estimated time–concentration curves. 
2.6.3. Statistical Analyses 
We used descriptive statistics (SigmaPlot, Version 11) to summarize the data for safety, toxicity, 
pharmacokinetics and clinical activity. 
3. Results 
3.1. Patients 
A detailed description of patient characteristics is presented in Table 2. All the patients received  
at least two doses of selenite and were evaluable for toxicity. Four patients stopped treatment because of 
DLT and two patients chose to discontinue in spite of no DLT. For one patient with progressing liver 
metastases, treatment was stopped due to quickly rising bilirubin. 
3.2. Dose Escalation, Toxicity and MTD 
Of the first 13 patients included, 12 received all planned selenite treatments. One of the patients  
died from acute pneumonia with heart complications after 19 treatments. Of the following 21 patients,  
13 received 10/10 planned selenite infusions. In a group of patients with advanced, progressing carcinoma 
and expected short survival, it was sometimes difficult to distinguish between the symptoms from the 
selenite treatment and symptoms from the progressing carcinoma, posing certain limitations on the side 
effects evaluations in the present study. There were hardly any symptoms of toxicity below 3.0 mg/m2 dose. 
The most common toxicities were nausea, vomiting and fatigue, observed at dose levels 4.5 mg/m2 and 
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higher (Table 3). No DLT was observed at doses ≤10.2 mg/m2. At 15.3 mg/m2 dose-level, DLTs were 
observed in 2/6 patients and the dose was reduced to 12.8 mg/m2 in the next study cohort, according to 
the dose-escalation rules of the study. At this dose, both the first and second patient had dose limiting 
toxicity. Thus, the MTD was considered to be 10.2 mg/m2. The highest cumulative dose given without 
any serious adverse events was 326 mg selenium during 12 days with no evidence of DLT in a 66 years 
old patient, at dose level 15.3 mg/m2. One patient with a throat obstacle from a hypo-pharyngeal 
carcinoma experienced vomiting after three selenite treatments, causing aspiration pneumonia, leading 
to death within a few days (Table 3).  
Table 2. Demographics and clinical characteristics of patients enrolled in SECAR trial. 
Characteristic 
Patients (N = 34) 
No. % 
Age, Years   
Mean 59.7 
SD 11 
Median 61.5 
Range 37–79 
Sex   
Male 19 56 
Female 15 44 
WHO performance status   
0 9 26.5 
1 19 55.9 
2 6 17.6 
Primary tumor types   
Non-small cell lung carcinoma 21 61.8 
Small-cell lung carcinoma 3 8.8 
Colon cancer 4 11.8 
Rectal cancer 2 5.9 
Malignant mesothelioma 1 2.9 
Ethmoidal cancer 1 2.9 
Tongue base cancer 1 2.9 
Testicular teratoma 1 2.9 
Stages   
Stage I 0 0 
Stage II 0 0 
Stage III 7 20.6 
Stage IV 27 79.4 
Refractory to first line therapy 34 100 
Abbreviations: WHO—World Health Organization; SD—Standard Deviation. 
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Table 3. Treatment-Emergent Clinically Significant Adverse Events (AEs) by Preferred Terms. 
Preferred Terms 
Grades 1–2 Grades 3–4 Any Grade 
No. % No. % No. % 
Alopecia 2 6 0 0 2 6 
Anorexia 3 9 0 0 3 9 
Anxiousness 0 0 1 3 1 3 
Arthralgia 2 6 0 0 2 6 
Chest pain 1 3 0 0 1 3 
Confusion 0 0 1 3 1 3 
Cramps in legs and/or finger 6 18 0 0 6 18 
Dyspnea 2 6 1 3 3 9 
ECG change 0 0 1 3 1 3 
Fatigue 16 47 2 6 18 53 
Garlic smell of breath 5 15 0 0 5 15 
Gastritis 1 3 0 0 1 3 
Hallucination 0 0 1 3 1 3 
Hot Flush 1 3 0 0 1 3 
Nausea 12 35 1 3 13 38 
Pain at infusion site 2 6 0 0 2 6 
Peripheral sensory and motor neuropathy 1 3 0 0 1 3 
Pressure on thorax 0 0 1 3 1 3 
Pruritus legs 1 3 0 0 1 3 
Stomach pain 1 3 0 0 1 3 
Stomach swelling 1 3 0 0 1 3 
Thrombopenia 1 3 0 0 1 3 
Unconsciousness 0 0 1 3 1 3 
Vertigo 1 3 0 0 1 3 
Vomiting 7 21 0 0 7 21 
Note: Adverse events of grade ≥ 3 were only observed at dose ≥ 12.8 mg/m2. 
The reasons to stop treatment in the four patients with selenite-induced DLT was confusion and 
hallucinations after four treatments in one patient at dose-level 15.3 mg/m2 due to possible interaction 
with a SSRI antidepressant drug (Mirtazapin); excessive fatigue and emesis after two treatments in another 
at the same dose-level; chest pain, anxiousness with signs of heart hypoxia on ECG and marginally 
increased Troponin T (but no myocardial infarction and normalized ECG within four days) in one 
patient; and unconsciousness, dyspnea and pronounced hypoxia with need of assisted breathing in the 
other, both at dose level 12.8 mg/m2 (Table 3). At higher doses, cramps of short duration in fingers and 
calves (similar to night cramps of the legs) and pain in the tumor were common. Garlic smell of breath 
was found in 15% of patients treated at dose levels of 3 mg/m2 and above. All toxicities except fatigue, 
a very subjective symptom, were reversible within one or two days. We did not observe any sequelae. 
There was no or very limited effect on routine blood tests (Figure 2). In a few patients above dose-level 
6.8 mg/m2, a mild thrombocytopenia (TC count not below 80,000/mL) was found. Clinically most of the 
patients were euthyroid during the whole follow up period except in few patients with aberrant 
triiodthyronin and thyroxin values. 
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Figure 2. Routine blood parameters in patients during the course of the treatment as a measure 
of systemic toxicity. Abbreviations: WBC—white blood cell count; TC—thrombocytes 
count; AST—aspartate amino transferase; ALT—alanine amino transferase; ALP—alkaline 
phosphatase; and LDH—lactate dehydrogenase. 155 × 131mm (300 × 300 DPI). 
 
Figure 3. Cont. 
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Figure 3. (A) Plasma selenium concentration in different cohorts receiving increasing 
concentration of sodium selenite during the first two-weeks of treatment. (B) Plasma selenium 
concentration–time curve in Patient 9. The daily dose (1.5 mg/m2) was given as a 20 min 
constant rate infusion. Start of infusions is indicated by the vertical lines. Measured serum 
concentrations are given by the filled circles. (C,D) Systemic selenium exposure is expressed 
as area under the serum concentration–time curve (µM*h). Figure 3C shows data from a single 
dose of selenite and data from the entire treatment period are presented in Figure 3D.  
(E,F) Figure 3E represent maximum concentration of selenium after a single dose of selenite. 
Maximum concentration of selenium during the entire treatment period is presented in  
Figure 3F. (G) Elimination half-life of selenium at different doses. In all the figures, filled 
circles indicate data from 20 min infusions and open circles data from 40 min infusions. 
Abbreviations: BI—before injection; AI—after injection; AUC—area under curve; and 
Cmax—maximum concentration 162 × 253mm (300 × 300 DPI). 
3.3. Pharmacokinetics 
The pharmacokinetic modeling was successful for data from all patients receiving all or most of the 
treatment. In eight patients who stopped early and in one patient who tested positive for HIV, there were 
no or not enough data to calculate any pharmacokinetic values. There was a close correlation between 
observed and predicted selenium concentration (correlation coefficient, r = 0.94 ± 0.05; mean ± standard 
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deviation). The result from the pharmacokinetic curve fitting procedure using data from one patient is 
given in Figure 3B. There was a linear increase of AUC with the dose both for data estimated for a single 
dose of selenium (given by the output from the used pharmacokinetic curve fitting program) and for repeated 
administration (Figure 3C,D). The maximum plasma concentration (Cmax) from a single dose of selenium 
increased with the dose in a non-linear pattern (Figure 3E). In contrast, there was a linear increase of 
observed Cmax of selenium during the entire study period with the total dose (Figure 3F). The median 
elimination half-life was 18.25 h (range 10.4–46.6 h) (Figure 3G). 
3.4. Clinical Assessment 
The antitumor effect was a secondary endpoint. Any antitumor effect described herein should be 
interpreted with precaution due inherent uncertainty associated with the limited number of patients on 
each dose level. Tumor size (RECIST) was evaluated before and after the selenite treatment and following 
subsequent chemotherapy treatment. The results from these measurements are presented in the waterfall 
plot (Figure 4A), suggesting no consistent effect of selenite treatment on the tumor volume. None of the 
patients had a complete or partial response immediately after respective treatments but 13 patients had 
a stable disease after selenite treatment and 16 patients after subsequent chemotherapy. Patient 4, who 
received a stent in the trachea and main bronchus to get relieved from the risk of compression-associated 
breathing difficulties a week before starting selenite treatment, had a stable disease with gradually improved 
response during the following six months. The tumor was undetectable half a year later as revealed by 
CT and a PET-CT examination. She is still alive without any recurrent tumor for more than six years.  
In six of the last patients included, a PET-CT examination with [18F]-2-fluoro-2-deoxy-D-glucose 
(FDG) was performed before and at the end of the selenite treatment. In one of these patients with 
testicular teratoma, SUVmax (Standardized Uptake Value for deoxyglucose in the tumor) increased after 
selenite treatment, indicating tumor-progression. In two patients (one with colon cancer and another with 
malignant mesothelioma) there were no changes. In three patients receiving 15.3 mg/m2, there were 
indications of a decreased uptake, albeit with some decreased uptake in the normal tissues in two of them. 
One patient with ethmoidal cancer (receiving 15.3 mg/m2), there was a clear decrease in SUVmax, 
indicating a prominent decrease in liver metastasis burden (Figure 4B). In general, we also found out 
that change in plasma M65 (a measure of intact and caspase-cleaved cytokeratin 18) values from baseline 
was significantly lower in patients with stable disease following selenite treatment (Supplementary  
Figure S2). 
In one patient with pleuritis, it was possible to address the modulatory effects of selenite treatment 
on the response of subsequent chemotherapy ex vivo following isolation of primary tumor cells from  
the pleura exudate. This was done before and after the selenite treatment. The cells were treated with 
carboplatin or gemcitabine and their combination ex vivo. The tumor cells were more sensitive to the 
combined carboplatin and gemcitabine treatment after the selenite treatment (Figure 4C). This patient 
had clinically and radiological determined tumor progression during the selenite treatment but regression 
when he was later treated with carboplatin and gemcitabine in combination. 
Incidences of chemotherapy-induced toxicity were higher in 100% patients given less than 3 mg/m2 
selenite in comparison to first line of treatment with the same drug(s) (supplementary Table S1). 
Therefore, it was registered as a need to decrease doses, prolong intervals between courses or to stop 
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chemotherapy altogether. However, chemotherapy-induced toxicity was higher in only 46% of the 
patients when given above 3 mg/m2 doses of selenite. 
 
Figure 4. (A) Waterfall plot showing tumor response following selenite treatment (top panel) 
and subsequent administration of chemotherapeutic drugs (bottom panel). In the waterfall 
plot, a positive value indicates increase in tumor volume and vice versa. (B) Anterior-posterior 
Maximum Intensity Projection (MIP) PET images of a 48 year old man with multiple metastases 
from a carcinoma of the left sinus ethmoidalis, acquired 60 min after iv administration of 
[18F]-2-fluoro-2-deoxy-D-glucose (FDG) (4 MBq/kg body weight); left panel, baseline 
examination; and right panel, examination after 17 days following stopping his selenite 
treatment (three treatments with 28.2 mg selenite a day). A few hours after the first treatment, 
his primary tumor, localized behind his left eye, started to swell, producing a massive 
increase of his earlier modest exophthalmos. However, it returned to the earlier status after 
1–2 days. This examination shows a general decrease of the FDG-uptake of the metastases, 
most evident in a large metastasis of the left liver lobe (arrow). (C) Toxicity of single or 
combined exposure of carboplatin and gemcitabine for 48 h to cells collected from pleural 
exudates from a patient. Fraction 1 indicates before selenite treatment and Fraction 2 
indicates after selenite treatment. Data are presented as mean ± S.D. 160 × 143 mm  
(300 × 300 DPI). 
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4. Discussion 
Selenium is known to be an essential micronutrient that can also elicit toxic effects in high concentrations. 
In this study, we report the first-in-human phase I trial to determine the MTD of iv administered sodium 
selenite in terminal cancer patients. One of the major aims of this study was to establish the safe dose 
level of selenite treatment. Sodium selenite was well tolerated in these patients at doses up to 10.2 mg/m2, 
therefore defined as MTD. At this dose and below, there were limited incidences of adverse events. Our 
observation was similar to what has been described earlier for selenite toxicity, mainly nausea, vomiting 
and fatigue—side effects that could be dose-limiting in spite of antiemetic treatment. The most 
significant adverse effects were heart toxicity with signs of ischemia, confusion, unconsciousness and 
impoverished breathing at dose level beyond MTD. Heart toxicity and breathing problems may be 
associated with negative impact of high dose of selenite on muscle contractility as had been earlier 
reported in perfused ex vivo heart and smooth muscles of rat and rabbit [25]. The dose limiting toxicity 
appeared some hours after selenium infusion, of short duration, not more than up to 6–8 h without any 
persisting toxicity or sequelae. Routine blood sample analyses indicated limited side-effects, transient in 
nature, if observed any. Notably, no bone marrow toxicity was evident.  
The pharmacokinetic data suggested linear increase in plasma selenium concentration with respect  
to total dose. However, the highest peak concentration reached a plateau at dose level ≥10.2 mg/m2. 
Notably, variable infusion time at these dose levels provided a window for plasma clearance and thereby 
precluded any direct comparison. In one patient (dose level 12.3 mg/m2), the renal clearance was 46% 
of the total selenium dose administered, suggesting important role of kidney in excretion of selenium 
from selenite. At the end of study termination, the plasma selenium concentration returned to the baseline 
levels, indicating no apparent adverse effects of high dose of repeated selenite administration on 
physiological selenium homeostasis.  
Selenite by itself was efficient in targeting certain tumors. However, a more pronounced effect was 
seen following subsequent chemotherapy in a subset of patients. From a clinical point of view, it is also 
known that single or combined use of cytostatic drugs might invoke tumor responses in certain patients 
after a time laps, although such phenomena are not common enough to justify repeated treatment with 
first line of treatment. Interestingly, many of the patients in our study responded again to their first line 
of chemotherapy, following which 13 patients were considered to have symptomatic benefit of the 
treatment. These in vivo effects corroborated well with the findings of the ex vivo study which 
demonstrated increased sensitivity towards identical chemotherapeutic drugs to patient-derived primary 
tumor cells. A recent study reported that selenite pre-treatment prevented the induction of carboplatin 
resistance in vivo in a nude mice model [26]. These results were in support of our findings and indicated 
that even if selenite in itself might be clinically useful in a subset of cancer patients; its subsequent use 
with chemotherapy might be therapeutically valuable.  
Efficacy results of selenite treatment should be interpreted with caution because of the small number 
of patients enrolled and overall survival data included the effect of subsequent chemotherapy. Evidence 
for clinical benefits was observed following selenite treatment as reflected by stable disease in 38% 
patients. This group of patients had relatively stable plasma level of M65, reflecting what had been found 
out earlier in testicular cancer following chemotherapy [27]. However, it is important to note that these 
observations do not demonstrate favorable effects of selenite on overall survival with a limited number 
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of patients. Albeit, it indicates that treatment with selenite and subsequent chemotherapy did not have a 
negative impact on survival. Two patients are still alive after six (CR) and one years, respectively. 
Besides, the median survival after the selenite treatment was 6.5 months, which might be considered a 
fairly long time in this group of treatment resistant, advanced tumors. Considering the advanced disease 
status and acquired resistance to the conventional chemotherapeutic treatments prior study enrollment 
in all patients, objective responses and stable disease in many patients are quite encouraging. 
In general, tumor cells harbor high basal level of reactive oxygen species (ROS), associated with 
adaptive response to increased metabolic need for uninterrupted growth [3]. Our hypothesis was to treat 
cancer patients using high dose of selenite implicated in ROS generation within the margin of appreciable 
therapeutic index. Our data showed that certain tumors were selenite-resistant. The differences in tumor 
response to selenite treatment perhaps attributed to inter-tumor heterogeneity and their microenvironment 
that regulate selenium uptake at the target tissue. Context wise, the roles of reducing extracellular redox 
milieu and expression of cystine-glutamate antiporter xCT [24] (facilitate selenium uptake from selenite) 
in tumor tissues warrant further investigation as major determinants of successful chemotherapeutic 
application of selenite. One of the major limitations of the present study was the absence of any quantitative 
measure of selenium loading into the tumor. A significant number of patients (70%) had lung carcinoma 
that precluded the possibility of obtaining tumor biopsies without significant risks. It is also unclear 
whether the duration of infusion was sufficient enough to obtain maximal antitumor effect, given that 
the plasma half-life of selenite was relatively short. A steady-state plasma concentration of sufficient duration 
might be necessary to achieve efficient chemotherapeutic effects. While addressing this, we found out 
that a human lung cancer cell line is highly sensitive to selenite when exposed to low concentration for 
longer period of time, with concomitant low selenium accumulation and vice versa (see supplementary 
data, Figure S1). Thus, we plan to proceed with another phase I study of prolonged selenite infusion to 
determine MTD and clinical effects to find an optimal treatment schedule. 
5. Conclusions  
In conclusion, selenite might represent an interesting cancer therapeutic for the treatment of some 
tumors and might also be an efficient complement for cytostatic regimes. Our results defining MTD, 
safety, pharmacokinetics and clinical presentation provide essential information for further effect 
evaluating studies of selenite in the treatment of cancer. The findings from the study also indicate that 
selenite might work in the three ways as mentioned earlier—by itself, in combination with chemotherapy 
and as a remedy against chemotherapy toxicity. However, further studies are needed to define if it might 
be of value in the clinic and also which individual therapeutic aspect might represents the best therapeutic 
approach. But first, further studies are needed to find the optimal treatment schedule. 
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